Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an
adjunctive medication during pterygium surgery in preventing pterygium recurrence. A
pterygium is a white fleshy growth on the surface of the eye, which can be removed
surgically. However, after surgical removal, pterygia can recur. One way of minimizing
recurrence is by applying a medication called mitomycin C to the surface of the eye during
pterygium surgery. However, mitomycin is associated with certain side effects, such as
thinning of the eye wall and poor wound healing. Bevacizumab has a different mechanism of
action and there is some evidence that it may be useful in preventing pterygium recurrence.
In this study, the safety and efficacy of adjunctive intraoperative use of bevacizumab and
mitomycin C for preventing pterygium recurrence will be directly compared.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston